TheMotleyFool
· Feb 23, 2026, 19:01 · 1 min read
Why ImmunityBio Stock Is Soaring Again Today
Shares of cancer immunotherapy specialist ImmunityBio (NASDAQ: IBRX) are up 16% as of noon ET on Monday after the company reported fourth-quarter earnings. The company's leading immunotherapy (and
I
ImmunityBio Inc.
26CA
6.68 €
-1.94 %
Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of cancers and diseases. While the bulk of ImmunityBio's business currently comes from U.S. sales of Anktiva, a treatment for bladder cancer cases that did not respond to the Bacille Calmette-Guérin (BCG) vaccine, the company is rapidly expanding.
Image source: Getty Images.
Source Fool.com
← Previous article
Why Viking Therapeutics Stock Is Up More Than 9% Today
Next article →
Here's Why Oracle Stock Slumped Today
Comments
The discussion is visible to sharewise members.